Panomic Approach to Immune-Connected Assays in Small Cell Lung Cancer
Recruiting now
Conditions studied: Small Cell Lung Cancer
In brief
The scope of the PICASSO project is to apply an innovative patient-based pan-omic approach to immune-assays, that will include multi-omics tumour characterization (genome, proteome, transcriptome), blood immune-cells and cytokine profiling, serological screening for paraneoplastic autoantibodies, clinical and metabolic measurements. The PICASSO project is aimed to validate in real world population the predictive role of SCLC transcriptomic classification (particularly, I-SCLC subtype) and to explore correlations with dynamic changes in peripheral blood immunity. Additionally, investigators expected to validate the predictive/prognostic role of emerging new variables, including metabolic-induced meta-inflammation alterations and subclinical auto-immunity.
Key facts
- Study ID
- NCT05797493
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- People needed
- 100
- Starts
- 2022-10-04
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2023-04-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- histologically- or cytologically-documented extensive-stage SCLC
- to have received upfront treatment with Cisplatin/Carboplatin, etoposide and anti PD1/PD-L1 inhibitors
- No evidence of brain metastases at diagnosis
- ECOG PS 0-2
- adult patients (aged ≥ 18 years) at diagnosis;
- signing of informed consent approved by the local Ethic Committee
You may not qualify if…
- none
Where it is running
- Fondazione Policlinico Gemelli IRCCS — Rome, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.